Oramed Pharmaceuticals (ORMP) Gross Margin (2016 - 2025)

Oramed Pharmaceuticals' (ORMP) quarterly Gross Margin came in at 0.65% in Q1 2025, down 99.35% on a QoQ basis from 100.0% in Q3 2019.

Oramed Pharmaceuticals (ORMP) Gross Margin (2016 - 2025) Analysis & Trends

Oramed Pharmaceuticals (ORMP) has 5 years of Gross Margin data on file, last reported at 0.65% in Q1 2025.

Quarterly Gross Margin changed N/A year-over-year to 0.65% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 0.65% (changed N/A YoY) and the FY2025 annual result came in at 0.65%, changed N/A from the prior year.
Gross Margin eased to 0.65% in Q1 2025, from 100.0% in the prior quarter.
In the past five years, Gross Margin ranged from a high of 0.65% in Q1 2025 to a low of 0.65% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	139.65 Bn	131.79 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	86.08 Bn	78.09 Bn	3.93 Bn	91.59%
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	90.43%
4	Moderna	63.25 Bn	58.11 Bn	52.00 Mn	35.86%
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.26 Bn	27.95 Bn	992.69 Mn	76.90%
7	BioNTech SE	28.96 Bn	10.57 Bn	668.28 Mn	63.27%
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.19 Bn	26.35 Bn	-	-
10	Oramed Pharmaceuticals	197.40 Mn	197.40 Mn	-	-

Download Data